ライフサイエンスコーパス: community-acquired

1 64% were males, and nearly all influenza was community acquired.

2 The majority of cases (75%) were community-acquired.

3 ired [8 d] vs healthcare associated [3 d] vs community acquired [3 d]), and median hospital costs (ho

4 ents screened, 678 individuals with SAB (24% community acquired, 56% healthcare associated, and 20% n

5 red [17 d] vs healthcare associated [7 d] vs community acquired [6 d]), median length of ICU stay (ho

6 38,369] vs healthcare associated [$8,796] vs community acquired [$7,024]).

7 [19.2%] vs healthcare associated [12.8%] vs community acquired [8.6%]).

8 The Swedish quality registry for community-acquired ABM was analyzed retrospectively.

9 2337 (58%) patients developed community-acquired acute kidney injury, with 889 (80%) o

10 pes and respiratory viruses during childhood community-acquired alveolar pneumonia (CAAP).

11 history of a neurosurgical procedure and had community-acquired anaerobic bacterial meningitis.

12 Community-acquired and health care-associated MERS-CoV i

13 Both community-acquired and hospital-acquired cases have been

14 reus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection world

15 in the absence of PBP4 was observed both in community-acquired and hospital-acquired MRSA strains, i

16 gionnaires' disease is an important cause of community-acquired and hospital-acquired pneumonia.

17 tes in children and adults, and against both community-acquired and household-acquired infections.

18 Norovirus is the leading cause of community-acquired and nosocomial acute gastroenteritis.

19 t species of this genus, known to cause both community-acquired and nosocomial infections worldwide.

20 ebsiella pneumoniae is an etiologic agent of community-acquired and nosocomial pneumonia.

21 The 30-day mortality in those with MDR community-acquired bacteraemia, healthcare-associated ba

22 Mortality related to community-acquired bacteremia decreased over the three s

23 lder patients, the mortality associated with community-acquired bacteremia decreased.

24 years who were hospitalized with first-time community-acquired bacteremia during 2000-2008 and 41,17

25 A total of 829 patients was diagnosed with community-acquired bacteremia during the study periods (

26 priate antibiotic therapy and development of community-acquired bacteremia in 1998 and 2007 were inde

27 The prevalence of community-acquired bacteremia in ICU patients has increa

28 The prevalence density rate of community-acquired bacteremia increased from nine per 10

29 Community-acquired bacteremia is associated with increas

30 te cardiovascular events, but the risk after community-acquired bacteremia is unknown.

31 and outcome of critically ill patients with community-acquired bacteremia over the past 15 yrs.

32 Patients with community-acquired bacteremia were significantly older a

33 tween socioeconomic status (SES) and risk of community-acquired bacteremia, as well as the contributi

34 arction and ischemic stroke within 1 year of community-acquired bacteremia.

35 d about the outcome of patients admitted for community-acquired bacteremia.

36 roke was greatly increased within 30 days of community-acquired bacteremia: 3.6% versus 0.2% among po

37 Adults with community acquired bacterial meningitis in Malawi presen

38 Adults with community acquired bacterial meningitis were included if

39 Information on community-acquired bacterial bloodstream infections (BSI

40 The case fraction of community-acquired bacterial BSIs in hospitalized patien

41 rom a nationwide cohort study of adults with community-acquired bacterial meningitis in the Netherlan

42 cale [GCS] score of </=8 for <12 hours) with community-acquired bacterial meningitis were randomized.

43 Community-acquired bacterial pneumonia (CABP) is a leadi

44 A total of 863 adults with community-acquired bacterial pneumonia (Pneumonia Outcom

45 dpoints in registrational clinical trials of community-acquired bacterial pneumonia and acute bacteri

46 e and Gram-negative pathogens known to cause community-acquired bacterial pneumonia.

47 ted 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia.

48 ravenous and oral option for monotherapy for community-acquired bacterial pneumonia.

49 phylococcus aureus is a common hospital- and community-acquired bacterium that can cause devastating

50 n isolates in a large panel of hospital- and community-acquired Bacteroides.

51 Salmonella enterica is a leading cause of community-acquired bloodstream infection in Africa.

52 Community-acquired bloodstream infections cause substant

53 Worldwide, the main pathogens of community-acquired BSI are nontyphoid salmonellae (NTS),

54 s desirable to understand the seasonality of community acquired (CA)-MRSA infections at the populatio

55 Community-acquired (CA) bacteremia with same species was

56 The incidence of community-acquired CDI was 10.3 per 100 000 persons and

57 agnosis of difficult-to-treat nosocomial and community acquired clinical infections and improved epid

58 tions due to C. difficile when evaluated for community-acquired diarrhea caused by other enteric path

59 rheal stool samples from patients with acute community-acquired diarrhea for non-O157 STEC in additio

60 t are significantly associated with invasive community-acquired disease in humans.

61 mial transmission and the rapid emergence of community-acquired ESBL challenge the routine use of con

62 Given that the majority of cases were community-acquired, estimates of the incidence of CDI th

63 potential emerging pathogen associated with community-acquired gastroenteritis and traveler's diarrh

64 orally associated samples from patients with community-acquired HPIV3 were analyzed.

65 es hospital-acquired hyponatremia (HAH) with community-acquired hyponatremia (CAH) in HF patients wit

66 criteria through sepsis, the infections were community acquired in 48.5% and hospital acquired in 51.

67 ented in 4 patients; 1 of these episodes was community acquired in the absence of any other comorbid

68 infection (OR, 2.752 [95% CI, 1.100-6.886]), community-acquired infection (OR, 10.432 [95% CI, 3.623-

69 rmpA (OR, 17.398 [95% CI, 4.224-71.668]) and community-acquired infection (OR, 6.844 [95% CI, 1.905-2

70 Melioidosis is an important cause of community-acquired infection in Southeast Asia and north

71 th Pneumocystis by cohabitation, to resemble community-acquired infection, underwent lung assessments

72 us is a leading cause of both nosocomial and community-acquired infection.

73 nce of nosocomial transmission compared with community-acquired infection?

74 ains have spread throughout hospitals, while community acquired infections and other sources ensure a

75 with shorter times to antimicrobial therapy: community-acquired infections (-53 min; p < 0.001) and h

76 he magnitude and term of morbidity of acute, community-acquired infections in immune competent patien

77 anges to antibiotic treatment guidelines for community-acquired infections of the upper and lower res

78 ntibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Ca

79 , has caused extensive hospital-acquired and community-acquired infections worldwide.

80 reas in the smaller group of inpatients with community-acquired infections, 12 capsid and 9 polymeras

81 Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant

82 hypervirulent strains associated with severe community-acquired infections.

83 g our ability to treat routine hospital- and community-acquired infections.

84 timicrobial resistance, especially regarding community-acquired infections.

85 thogen and a leading cause of nosocomial and community-acquired infections.

86 the etiological agent of many hospital- and community-acquired infections.

87 ial resistance in both hospital-acquired and community-acquired infections.

88 esity were associated with increased risk of community-acquired infectious diseases, especially infec

89 Adjusted vaccine effectiveness in preventing community-acquired influenza was 31% (95% confidence int

90 t protection (62% [95% CI, 17%-82%]) against community-acquired influenza was demonstrated.

91 nted the first case with abscesses caused by community-acquired K. pneumoniae in the kidneys and sple

92 Episodes of community-acquired listerial meningitis confirmed by cer

93 d before lumbar puncture (LP) in adults with community-acquired meningitis (CAM).

94 isolates and is present in almost all USA300 community-acquired methicillin-resistant S. aureus (CA-M

95 00, the clonal type associated with epidemic community-acquired methicillin-resistant S. aureus (MRSA

96 ogenic bNOS-deficient mutant in the epidemic community-acquired methicillin-resistant S. aureus (MRSA

97 sons, we sought to develop a murine model of community-acquired methicillin-resistant S. aureus SSTI

98 In the United States, an epidemic of community-acquired methicillin-resistant Staphylococcus

99 of various antibiotic regimens in the era of community-acquired methicillin-resistant Staphylococcus

100 ntinue to play an important role in treating community-acquired methicillin-resistant Staphylococcus

101 ily a nosocomial infection, the incidence of community-acquired methicillin-resistant Staphylococcus

102 th suppression of USA300, the most prevalent community-acquired methicillin-resistant Staphylococcus

103 The incidence of community-acquired methicillin-resistant Staphylococcus

104 The recent spread of community-acquired methicillin-resistant Staphylococcus

105 d by Staphylococcus aureus, particularly the community-acquired methicillin-resistant strains of S. a

106 n is essential for beta-lactam resistance in community-acquired, methicillin-resistant S. aureus (MRS

107 a pandemic clonal lineage of hypervirulent, community-acquired, methicillin-resistant Staphylococcus

108 d >5000 individuals comprising patients with community-acquired mild lower respiratory tract infectio

109 In this series we report 3 cases of community-acquired MRSA acute dacryoadenitis in adults p

110 ith persistent bacteremia and 2 prototypical community-acquired MRSA strains, as well as their respec

111 x (FICI) of 0.1 with methicillin against the community-acquired MRSA USA300 strain, indicating strong

112 The genotypes in community-acquired NoV infections were more heterogeneou

113 notypes among inpatients with nosocomial and community-acquired NoV infections, respectively.

114 d factors and causes hospital infections and community-acquired ocular infections.

115 tics for Legionella spp in all patients with community-acquired or hospital-acquired pneumonias is a

116 which is usually the case for high-morbidity community-acquired pathogens like HIV, Influenza and Den

117 performed a genetic association study in 469 community-acquired pneumococcal meningitis cases and 207

118 s from nasopharyngeal (NP) swabs distinguish community-acquired pneumococcal pneumonia (CAP) from asy

119 ociated with a poor outcome in patients with community acquired pneumonia (CAP).

120 nary sarcoidosis, pulmonary tuberculosis, to community acquired pneumonia and primary lung cancer and

121 developed to predict the 30 day mortality in community acquired pneumonia; however, several guideline

122 acute myocardial infarction (2.85 days) and community-acquired pneumonia (2.22 days).

123 them to a cohort of patients with bacterial community-acquired pneumonia (B-CAP).

124 Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia (CAP) across patient popula

125 Community-acquired pneumonia (CAP) affects >5 million ad

126 , 5, 7F, and 19A were the most implicated in community-acquired pneumonia (CAP) after implementation

127 linical effectiveness of PPV23 in preventing community-acquired pneumonia (CAP) among the general pop

128 en aged <18 years who were hospitalized with community-acquired pneumonia (CAP) and children asymptom

129 neumoniae causes a substantial proportion of community-acquired pneumonia (CAP) and healthcare-associ

130 Prevalence of Staphylococcus aureus community-acquired pneumonia (CAP) and its clinical feat

131 , rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsi

132 ent pneumonia following hospitalization with community-acquired pneumonia (CAP) are poorly understood

133 Clinical decision making relative to community-acquired pneumonia (CAP) diagnosis is difficul

134 ggest that statins may benefit patients with community-acquired pneumonia (CAP) due to antiinflammato

135 availability, but hospitalized patients with community-acquired pneumonia (CAP) generally are treated

136 ng proton pump inhibitor (PPI) exposure with community-acquired pneumonia (CAP) have reported either

137 In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in

138 quent lack of a microbiological diagnosis in community-acquired pneumonia (CAP) impairs pathogen-dire

139 Inhaled corticosteroids (ICS) increase community-acquired pneumonia (CAP) incidence in patients

140 Community-acquired pneumonia (CAP) is a leading cause of

141 Previous reports suggest that community-acquired pneumonia (CAP) is associated with an

142 Community-acquired pneumonia (CAP) is common and often s

143 Understanding the burden of community-acquired pneumonia (CAP) is critical to alloca

144 Information on the long-term prognosis after community-acquired pneumonia (CAP) is limited.

145 ficance of viruses detected in patients with community-acquired pneumonia (CAP) is often unclear.

146 Community-acquired pneumonia (CAP) is the major manifest

147 Community-acquired pneumonia (CAP) remains one of the mo

148 The effect of body mass index (BMI) on community-acquired pneumonia (CAP) severity is unclear.

149 tment for patients with clinically suspected community-acquired pneumonia (CAP) who are admitted to n

150 g cause of respiratory infections, including community-acquired pneumonia (CAP).

151 ons with HCAP compared with populations with community-acquired pneumonia (CAP).

152 ostic indicator in persons hospitalized with community-acquired pneumonia (CAP).

153 gen detection for patients hospitalized with community-acquired pneumonia (CAP).

154 used previously to determine the etiology of community-acquired pneumonia (CAP).

155 -acquired pneumonia (HAP) when compared with community-acquired pneumonia (CAP).

156 dy of 445 pneumonia patients, including both community-acquired pneumonia (CAP; n = 124) and HCAP (n

157 sepsis due to fecal peritonitis (n = 117) or community-acquired pneumonia (n = 126), and of control s

158 ute respiratory distress syndrome induced by community-acquired pneumonia (n=10), CXCR1 and CXCR2 exp

159 88; n = 921 participants), and S. pneumoniae community-acquired pneumonia (OR = 2.15; 95% CI = 1.32-3

160 Postobstructive community-acquired pneumonia (PO-CAP) is relatively comm

161 f viral infections in the etiology of severe community-acquired pneumonia (SCAP) was prospectively ev

162 Incidence estimates of hospitalizations for community-acquired pneumonia among children in the Unite

163 ospitals involving patients with both severe community-acquired pneumonia and a high inflammatory res

164 gionella are recognised as a common cause of community-acquired pneumonia and a rare cause of hospita

165 We describe severe community-acquired pneumonia and bacteremia caused by He

166 o UK intensive care units with sepsis due to community-acquired pneumonia and evidence of organ dysfu

167 Among patients with severe community-acquired pneumonia and high initial inflammato

168 ntigen detection assay were used to identify community-acquired pneumonia and invasive pneumococcal d

169 e (the pneumococcus) is the leading cause of community-acquired pneumonia and is now recognized to be

170 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and nasal carriage is a pre

171 udomonas pneumonia, and associations between community-acquired pneumonia and risks or outcomes have

172 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and sepsis, with adult hosp

173 Streptococcus pneumoniaeis a major cause of community-acquired pneumonia and septicemia in adults.

174 on treatment in critically ill patients with community-acquired pneumonia and support current guideli

175 pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive p

176 oniae continues to be a significant cause of community-acquired pneumonia and, on rare occasions, man

177 ving extracorporeal membrane oxygenation for community-acquired pneumonia between 2002 and 2012.

178 gnosed diabetes mellitus in a large European community-acquired pneumonia cohort.

179 ty-acquired pneumonia included in the German Community-Acquired Pneumonia Competence Network (CAPNETZ

180 al multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010

181 hage, trauma, acute renal failure, or severe community-acquired pneumonia did not differ statisticall

182 nary samples from 196 Tunisian patients with community-acquired pneumonia during the period 2009-2010

183 e pneumococcal disease but not in preventing community-acquired pneumonia from any cause.

184 a cohort study including adult patients with community-acquired pneumonia from two Spanish university

185 nter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted

186 In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adult

187 nts, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age o

188 CV13) against first episodes of vaccine-type community-acquired pneumonia in adults aged >/=65 years

189 Data on outcomes from severe community-acquired pneumonia in adults receiving rescue

190 Coccidioidomycosis is a common cause of community-acquired pneumonia in areas of the southwester

191 Child Health (PERCH) study, a large study of community-acquired pneumonia in children aged 1-59 month

192 olipid lysoPCaC26:1 identified patients with community-acquired pneumonia in sepsis or severe sepsis/

193 butes to the pathogenesis of childhood acute community-acquired pneumonia in settings with a high tub

194 usefulness as prompt tools for patients with community-acquired pneumonia in the emergency department

195 ny and Austria encompassing 1961 adults with community-acquired pneumonia included in the German Comm

196 Community-acquired pneumonia is a leading infectious cau

197 Community-acquired pneumonia is commonly caused by Strep

198 es mellitus and prediabetes in patients with community-acquired pneumonia is largely unknown.

199 21.8 to 62.5), nonbacteremic and noninvasive community-acquired pneumonia occurred in 33 persons in t

200 s of infections due to vaccine-type strains, community-acquired pneumonia occurred in 49 persons in t

201 37.7%, 41.1%, and 75.8%, respectively), and community-acquired pneumonia occurred in 747 persons in

202 f recombinant TFPI to treat severe sepsis in community-acquired pneumonia or to achieve improved engr

203 hospitalized with radiographically confirmed community-acquired pneumonia published from January 1, 1

204 is a recommended treatment for patients with community-acquired pneumonia requiring hospital admissio

205 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a

206 lculated population-based incidence rates of community-acquired pneumonia requiring hospitalization a

207 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a

208 The incidence of community-acquired pneumonia requiring hospitalization w

209 iae is the most common causative organism in community-acquired pneumonia responsible for millions of

210 The majority (66%) of adults with community-acquired pneumonia supported on extracorporeal

211 a pathogenic bacterium and a major cause of community-acquired pneumonia that could be fatal if left

212 ts) and patients admitted with sepsis due to community-acquired pneumonia to 29 ICUs in the UK (secon

213 4.7%, 78.2%, 75%, and 87%, respectively, for community-acquired pneumonia validated against a blinded

214 burden of hospitalization for children with community-acquired pneumonia was highest among the very

215 Research Team (PORT) risk class III-IV acute community-acquired pneumonia were randomly assigned (1:1

216 occus pneumoniae is the most common cause of community-acquired pneumonia worldwide.

217 dromes (including bloodstream infections and community-acquired pneumonia) in children and neonates (

218 emic inflammatory response syndrome, 100 for community-acquired pneumonia, 112 for urinary tract infe

219 possibly spontaneous bacterial peritonitis, community-acquired pneumonia, and infection with Mycobac

220 , nonbacteremic and noninvasive pneumococcal community-acquired pneumonia, and invasive pneumococcal

221 during a lower respiratory tract infection, community-acquired pneumonia, and pneumonia associated w

222 In adults hospitalized with community-acquired pneumonia, antibiotic therapy consist

223 IPD and the most resource-intensive type of community-acquired pneumonia, hospital-treated pneumonia

224 1 are associated with unfavorable outcome in community-acquired pneumonia, intra-abdominal infections

225 f almost 10,000 critically ill patients with community-acquired pneumonia, macrolide use was associat

226 odes of vaccine-type strains of pneumococcal community-acquired pneumonia, nonbacteremic and noninvas

227 Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-conf

228 In patients with severe community-acquired pneumonia, treatment failure is assoc

229 tes mellitus is an important risk factor for community-acquired pneumonia, whereas the prevalence of

230 of 278 consecutive patients hospitalized for community-acquired pneumonia, who were followed up until

231 iae is the most common causative pathogen in community-acquired pneumonia.

232 ute respiratory distress syndrome induced by community-acquired pneumonia.

233 treatment of Asian patients with PORT III-IV community-acquired pneumonia.

234 ute respiratory distress syndrome induced by community-acquired pneumonia.

235 of Asian patients admitted to hospital with community-acquired pneumonia.

236 ide therapy for critically ill patients with community-acquired pneumonia.

237 her regimens in critically ill patients with community-acquired pneumonia.

238 iae is the most common causative pathogen in community-acquired pneumonia.

239 factor (MIF) have been linked to the risk of community-acquired pneumonia.

240 e of hospitalization of patients affected by community-acquired pneumonia.

241 r amoxicillin for children hospitalized with community-acquired pneumonia.

242 al use of corticosteroids in severe cases of community-acquired pneumonia.

243 m monotherapy for children hospitalized with community-acquired pneumonia.

244 secutively collected patients diagnosed with community-acquired pneumonia.

245 to compare these with the same parameters in community-acquired pneumonia.

246 uman nasopharynx and is the leading cause of community-acquired pneumonia.

247 ealthcare-associated pneumonia (HCAP) versus community-acquired pneumonia.

248 ptococcus pneumoniae is the leading cause of community-acquired pneumonia.

249 gnosed diabetes mellitus was prevalent among community-acquired pneumonia.

250 ged 1-59 months enrolled in a large study of community-acquired pneumonia.

251 rveillance study of adults hospitalized with community-acquired pneumonia.

252 making analysis of Sepsis-3 in patients with community-acquired pneumonia.

253 ing acute respiratory disease (ARD), such as community-acquired pneumonia.

254 ors for poor outcomes in adult patients with community-acquired pneumonia.

255 is the cornerstone of medical management for community-acquired pneumonia.

256 pneumoniae is a major causative pathogen in community-acquired pneumonia; together with influenza vi

257 ics included healthcare-associated (53%) and community-acquired pneumonias (17%).

258 Klebsiella pneumoniae causing community-acquired pyogenic liver abscess complicated wi

259 Community-acquired respiratory distress syndrome (CARDS)

260 DP-ribosylating and vacuolating toxin called community-acquired respiratory distress syndrome (CARDS)

261 e (mART) and vacuolating activities known as Community-Acquired Respiratory Distress Syndrome Toxin (

262 Community-acquired respiratory virus (CARV) infections h

263 Community-acquired respiratory virus (CARV) infections o

264 rea worthy of focus is the interface between community-acquired respiratory viruses and the respirato

265 Despite the dominant role of community-acquired respiratory viruses as etiological ag

266 dren aged younger than 5 years who died with community-acquired RSV infection between Jan 1, 1995, an

267 large case series of children who died with community-acquired RSV infection.

268 A postvaccination decrease in hospitalized community-acquired RV infections by 89.3% was seen in al

269 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) ha

270 tion of patients with IE was 22% (36/166) in community-acquired SAB, 11% (40/378) in community-onset

271 Community-acquired SAB, presence of cardiac device, and

272 l emergency medical services encounters with community acquired sepsis transported to the hospital.

273 f the study was to estimate the incidence of community-acquired sepsis based on patients' symptoms an

274 ative agent of melioidosis, a common form of community-acquired sepsis in Southeast Asia.

275 ong 58,934 prehospital encounters, 2,683 had community-acquired sepsis, with an in-hospital mortality

276 ital mortality among patient encounters with community-acquired sepsis.

277 are associated with in-hospital mortality in community-acquired sepsis.

278 to consecutive critically ill patients with community-acquired severe acute respiratory infection of

279 ies, severe sepsis hospitalizations included community-acquired severe sepsis (62.8%), healthcare-ass

280 exhibited higher in-hospital mortality than community-acquired severe sepsis (hospital acquired [19.

281 gher mortality and resource utilization than community-acquired severe sepsis and healthcare-associat

282 We defined community-acquired severe sepsis as all other severe sep

283 pidemiologic studies have not differentiated community-acquired severe sepsis from healthcare-associa

284 ith severe sepsis, including 193,081 (62.8%) community-acquired severe sepsis, 79,581 (25.9%) healthc

285 Prevalence of community-acquired severe sepsis, healthcare-associated

286 We sought to compare and contrast community-acquired severe sepsis, healthcare-associated

287 both healthcare-associated severe sepsis and community-acquired severe sepsis, with higher median len

288 d for patients with and without asplenia and community-acquired severe sepsis/septic shock.

289 one of the most common etiological agents of community-acquired skin and soft tissue infection (SSTI)

290 as isolates obtained from or associated with community-acquired sources of Legionnaires' disease.

291 epresentation of hospital-acquired SSTI than community-acquired SSTI, and they involve methods that a

292 Although the majority of S. aureus community-acquired SSTIs are uncomplicated and self-clea

293 rea to determine the nature (clonal type) of community-acquired Staphylococcus aureus strains causing

294 findings to those for E. coli isolates from community-acquired urinary tract infections (UTI) that o

295 cherichia coli, a common agent of sepsis and community-acquired urinary tract infections, obtained du

296 ignature in UPEC during naturally occurring, community acquired UTI in women and multiple novel fitne

297 ed to E. coli strains isolated from cases of community-acquired UTI, those isolated from cases of men

298 f IE in France and to compare the profile of community-acquired versus healthcare-associated IE.

299 hould focus on differentiating resistance in community-acquired versus hospital-acquired infections,

300 ) infections are still frequently treated as community-acquired with a detrimental effect on survival